HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions.

Abstract
Graft-versus-host disease (GVHD) induced by transplant-derived T cells represents a major complication after allogeneic bone marrow transplantation (BMT). However, these T cells support engraftment, early T-cell immunity, and mediate the graft-versus-tumor (GVT) effect. Cytotoxic effector functions by transplanted T cells are predominantly mediated by the perforin/granzyme and the CD95/CD95L system. APG101, a novel recombinant human fusion protein consisting of the extracellular domain of CD95 and the Fc domain of an IgG1 antibody inhibited CD95L-induced apoptosis without interfering with T-cell function in vitro and was therefore tested for its ability to prevent GVHD in murine BMT models across minor or major histocompatibility barriers. Starting APG101 treatment either 1 day before or 6 days after transplantation effectively reduced clinical GVHD and rescued survival between 60% and 100% if GVHD was CD95L mediated. APG101 did not interfere with the GVT effect, because P815 mastocytoma and most importantly primary Bcr-Abl-transformed B-cell leukemias were completely eradicated by the alloantigen-specific T cells. Phenotype and homing of alloantigen-specific T cells or their perforin/granzyme-mediated cytotoxicity and proliferative capacity were not affected by APG101 treatment suggesting that APG101 therapy might be useful in GVHD prophylaxis without impairing T-cell function and most importantly preserving GVT activity.
AuthorsNatalie Hartmann, Joanna J Messmann, Frank Leithäuser, Maxi Weiswange, Michael Kluge, Harald Fricke, Klaus-Michael Debatin, Gudrun Strauss
JournalBlood (Blood) Vol. 121 Issue 3 Pg. 556-65 (Jan 17 2013) ISSN: 1528-0020 [Electronic] United States
PMID23203823 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Immunoglobulin G
  • Recombinant Fusion Proteins
  • fas Receptor
  • APG101
Topics
  • Animals
  • Apoptosis (drug effects, immunology)
  • Bone Marrow Transplantation (adverse effects, immunology)
  • Cell Division (drug effects, immunology)
  • Cell Movement (drug effects, immunology)
  • Disease Models, Animal
  • Female
  • Graft vs Host Disease (immunology, prevention & control)
  • Immunoglobulin G (immunology, pharmacology)
  • Immunophenotyping
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Neoplasms (immunology)
  • Recombinant Fusion Proteins (immunology, pharmacology)
  • T-Lymphocytes, Cytotoxic (drug effects, immunology)
  • Transplantation, Homologous
  • fas Receptor (immunology, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: